International Biomedical Devices, Inc. Closes Initial Round of Seed Funding

FOR IMMEDIATE RELEASE International Biomedical Devices, Inc. Closes Initial Round of Seed Funding Mount Pleasant, SC-­‐ August 12, 2015-­‐ International Biomedical Devices, Inc. (IBMD), an early-­stage medical device company focused on the emerging, non-­‐laser based, precision capsulotomy category for cataract surgery, today announced the closing of its seed funding round. This initial round of funding raised […]

logo_365935_printFOR IMMEDIATE RELEASE

International Biomedical Devices, Inc. Closes Initial Round of Seed Funding

Mount Pleasant, SC-­‐ August 12, 2015-­‐ International Biomedical Devices, Inc. (IBMD), an early-­stage medical device company focused on the emerging, non-­‐laser based, precision
capsulotomy category for cataract surgery, today announced the closing of its seed funding round.

This initial round of funding raised $2.0 million (US) in exchange for Series Seed preferred stock, which will be used to fund product development and pre-­‐clinical studies of IBMD’s flagship
product, the ApertureRx™ Precision Capsulotomy System (ApertureRx). The ApertureRx is designed to create a precise incision during a cataract surgery procedure and simplify capsulotomy creation. The original offering was oversubscribed, with financing coming from SCRA Technology Ventures’ SC Launch program, angel investors and management.

“This round of funding will enable us to finalize development of a commercial-­‐ready system and complete certain preclinical tests toward regulatory review of our lead product, the ApertureRx
Precision Capsulotomy System,” said Steven R. Bryant, Founder and CEO of IBMD. “We are excited about our ability to continue innovation on this new device, which we feel will be important for
assisting ophthalmic surgeons in creating a perfect capsulotomy, every time, during cataract surgery.”

The ApertureRx may increase the safety of cataract surgery while helping to create more predictable visual outcomes for patients. By simplifying the current manual procedure, a broader range of
surgeons throughout the world will be able to achieve surgical incisions with precise placement and a high degree of consistency. A growing body of evidence indicates that a perfectly round
capsulotomy during cataract surgery results in more precise sizing and centering, better IOL-capsule overlap parameters, less IOL tilt and decentration, ultimately leading to a more
stable refractive result. Traditionally, the capsulotomy procedure is performed utilizing a manual technique. This technique requires a high-­‐degree of skill and
can sometimes lead to unpredictable results.

About International Biomedical Devices, Inc.
International Biomedical Devices, Inc. (IBMD) is an early-­‐stage medical device company focused in ophthalmic innovations. At present the company is leading the emerging, non-­‐laser based,
precision capsulotomy category through the development of a unique and needed new capsulotomy technology. The arrival of this device represents a considerable potential improvement to
traditional surgical technique by ensuring safer, more precise cataract surgeries and more predictable outcomes for patients.

# # #

Media Contact:
Allison Potter
Pascale Communications, LLC mobile: 412.228.1678
email: allison@pascalecommunications.com


About the Author

 

Leave Comment

Yay! You've decided to leave a comment. That's fantastic! Please keep in mind that comments are moderated. .... 

Be the first to comment “International Biomedical Devices, Inc. Closes Initial Round of Seed Funding”